Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TitAIN phase 2 trial of secukinumab in giant cell arteritis
2018-002610-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Secukinumab arm with Placebo arm (2 arms). Primary endpoint: Sustained remission at Week 28. Started Aug 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2018-002610-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002610-12.